The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
1 other identifier
interventional
28
1 country
1
Brief Summary
The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 10, 2024
CompletedFirst Submitted
Initial submission to the registry
July 18, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 18, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 18, 2024
CompletedFirst Posted
Study publicly available on registry
July 24, 2024
CompletedJuly 24, 2024
July 1, 2024
1 month
July 18, 2024
July 23, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
erythema index
The change rate in lesion clearance of face at 1 month after treatment will be measured as the primary outcome
0、1、2、4 week
Study Arms (2)
The Application of Bovine Basic Fibroblast Growth Factor Gel
EXPERIMENTALBovine Basic Gel
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Sensitive skin with a diagnosis of persistent erythema and a lactate irritation test score of 2-3
- No related skin care products including bovine alkaline fibroblast growth factor were used within 1 month before participating in the experiment, and photoelectric treatment measures were not carried out
- Physical sunscreen should be strict during enrollment
You may not qualify if:
- Children
- Have serious heart, liver, kidney, and blood system diseases, and severe immunocompromise
- Patients with mental illness or cancer
- Those who have received glucocorticoids, calcineurin inhibitors, topical small molecule drugs, antibiotics or tretinoin within 3 months
- Those who are allergic to basic fibroblast growth factor gel and its components
- Acute dermatitis of the face and perifolliculitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shanghai Skin Disease Hospital
Shanghai, China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 18, 2024
First Posted
July 24, 2024
Study Start
June 10, 2024
Primary Completion
July 18, 2024
Study Completion
July 18, 2024
Last Updated
July 24, 2024
Record last verified: 2024-07